There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Baudax Bio (BXRX – Research Report) and Axcella Health (AXLA – Research Report) with bullish sentiments. Baudax Bio (BXRX) Noble Financial analyst Gregory Aurand maintained a Buy rating on Baudax Bio today and set a price target of $8.00. The company's shares closed last Thursday at $1.44, close to its 52-week low of $1.38. According to TipRanks.com, Aurand is ranked #7524 out of 7891 analysts. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baudax Bio with a $6.50 average price target.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-baudax-bio-bxrx-and-axcella-health-axla?utm_source=advfn.com&utm_medium=referral
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Baudax Bio Charts.
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Baudax Bio Charts.